Cargando…

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartoletti, Michele, Pelizzari, Giacomo, Gerratana, Lorenzo, Bortot, Lucia, Lombardi, Davide, Nicoloso, Milena, Scalone, Simona, Giorda, Giorgio, Baldassarre, Gustavo, Sorio, Roberto, Puglisi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312982/ https://www.ncbi.nlm.nih.gov/pubmed/32471250 http://dx.doi.org/10.3390/ijms21113805

Ejemplares similares

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors
por: Garutti, Mattia, et al.
Publicado: (2019)

Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
por: Basile, Debora, et al.
Publicado: (2019)

TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
por: Sonego, Maura, et al.
Publicado: (2019)

Paraneoplastic cerebellar degeneration associated with ovarian cancer
por: RUSSO, ALESSIA ERIKA, et al.
Publicado: (2013)

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
por: Dall’Acqua, Alessandra, et al.
Publicado: (2021)

Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis
por: Garziera, Marica, et al.
Publicado: (2015)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker
por: Pelizzari, Giacomo, et al.
Publicado: (2019)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
por: Dall'Acqua, Alessandra, et al.
Publicado: (2017)

Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study
por: Giorda, Giorgio, et al.
Publicado: (2014)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
por: Viotto, Davide, et al.
Publicado: (2020)

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
por: Garziera, Marica, et al.
Publicado: (2019)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices
por: Bartoletti, M., et al.
Publicado: (2021)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
por: Sonego, Maura, et al.
Publicado: (2017)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
por: Azzalini, Eros, et al.
Publicado: (2022)

APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC
por: Malfatti, Matilde Clarissa, et al.
Publicado: (2019)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2020)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
por: Liapi, Aikaterini, et al.
Publicado: (2023)

Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies
por: Cucciniello, Linda, et al.
Publicado: (2022)

PARP12 is required for mitochondrial function maintenance in thermogenic adipocytes
por: Hu, Fan, et al.
Publicado: (2022)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_95hn0422eaoa7pdgdddv1946g6